Skip to main content
Evolva Holding SA logo

Evolva Holding SA — Investor Relations & Filings

Ticker · EVE ISIN · CH1262055788 LEI · 506700IF701J35J34N57 SW Financial and insurance activities
Open in API
Filings indexed 77 across all filing types
Latest filing 2022-11-29 Regulatory Filings
Country CH Switzerland
Listing SW EVE

About Evolva Holding SA

https://evolva.com/

EvoNext Holdings SA, formerly Evolva Holding SA, is a biotechnology company that researches, develops, and commercializes nature-based ingredients. The company focuses on providing innovative and sustainable solutions for various industries, with primary applications in flavors and fragrances, health ingredients, and nutrition. Its mission is to leverage biotechnology to discover and produce high-quality ingredients for health and wellness markets.

Recent filings

Filing Released Lang Actions
Evolva: Update on activities to boost Resveratrol
Regulatory Filings Classification · 98% confidence The document is a press release dated November 29, 2022, providing an update on the commercial activities and milestones achieved for the product 'Resveratrol' across dietary supplements, animal nutrition, and cosmetics. It discusses business strategy, market expansion (Brazil approval), and upcoming events (Full-year results, AGM). It is not a formal regulatory filing like a 10-K, nor is it a transcript (CT) or a formal dividend notice (DIV). Since it provides operational and commercial updates, it is best classified as a general corporate update. Given the options, it most closely resembles an announcement that doesn't fit the highly specific financial report categories. However, it is a detailed business update, not just a short announcement of a report. It is not an Earnings Release (ER) as it doesn't contain period-end financial results, but rather operational progress. It is not a Management Discussion & Analysis (MDA) as it lacks the comprehensive financial review. Since it details business activities and progress, and is not a formal statutory report, it falls under the general category of corporate news. Given the available codes, and since it is a detailed update on business activities rather than a formal financial report or a simple announcement of a report, it is closest to a general regulatory filing/announcement that doesn't fit elsewhere, which points towards RNS, or potentially an Investor Presentation (IP) if it were structured as slides, but it reads like a news release. Since it is a detailed update on business activities and strategy implementation, and not a formal financial report, RNS (Regulatory Filings/Miscellaneous) is the most appropriate fallback, although it contains elements of an Investor Presentation narrative. Given the content focuses on operational updates and market progress, RNS is the safest general classification for non-statutory, non-earnings news releases.
2022-11-29 English
Evolva receives approval for Veri-teTM Resveratrol for animal health in Brazil
Regulatory Filings Classification · 95% confidence The document is a press release dated November 10, 2022, announcing that Evolva received regulatory approval in Brazil for its Veri-teTM Resveratrol product for animal health. It details the scope of the approval and mentions future dates for financial results and the AGM. This type of announcement, which communicates a specific, non-financial event (regulatory approval) via a news release format, does not fit the definitions for 10-K, ER, IR, or CT. Since it is a specific corporate announcement that isn't related to management changes (MANG), director dealings (DIRS), dividends (DIV), or capital structure (CAP/SHA), the most appropriate general category for a significant, non-standard corporate update that isn't a full report is the fallback category, Regulatory Filings (RNS), as it is a regulatory event announcement.
2022-11-10 English
Evolva receives grant from US CDC in the amount of USD 540,000
Regulatory Filings Classification · 99% confidence The document is a press release dated October 21, 2022, announcing that Evolva Holding SA received a grant of USD 540,000 from the US CDC for product development. It details the purpose of the grant, quotes management, and provides future dates for results and the AGM. This type of announcement, which details a specific, non-financial event (like a grant award) that impacts the company's operations and future outlook, is best classified as a general regulatory announcement or news release that doesn't fit the highly specific categories like ER, 10-K, or CAP. Since it is a general corporate news item that doesn't fit other specific categories (like dividend, management change, or financing), the most appropriate fallback category is Regulatory Filings (RNS), which serves as a catch-all for significant, non-standard announcements.
2022-10-21 English
Evolvas NootkaSHIELDTM insect repellent approved in Hong Kong
Regulatory Filings Classification · 100% confidence The document is a press release dated October 11, 2022, announcing a product approval (NootkaSHIELD™ insect repellent) in Hong Kong and mentioning future market launches and past regulatory approvals (US EPA). It contains key business updates, quotes from management, and important dates for future corporate events (like the AGM and full-year results). This type of announcement, focusing on operational milestones, product news, and general corporate updates that don't fit specific financial reporting categories (like 10-K, ER, or DIV), is best classified as a general Regulatory Filing or News Release. Since it is not a formal financial report, a transcript, or a specific regulatory form like DIRS or DEF 14A, the most appropriate general category is Regulatory Filings (RNS), which serves as a broad category for miscellaneous regulatory announcements.
2022-10-11 English
Evolva business update: Continued good business momentum
Earnings Release Classification · 100% confidence The document is a press release dated October 6, 2022, titled "Evolva business update: Continued good business momentum." It provides key financial highlights for the first 9 months and Q3 2022 (revenues, gross contribution margin) and confirms the company is on track to meet its full-year 2022 targets. This content structure—a brief announcement of recent performance metrics and outlook confirmation—is characteristic of an Earnings Release (ER). It is not a comprehensive Annual Report (10-K) or a detailed Interim Report (IR), but rather the initial announcement of period results. 9M 2022
2022-10-06 English
Evolva with record half-yearly sales and new mid-term plan
Earnings Release Classification · 100% confidence The document is explicitly labeled as an 'Ad-hoc' announcement and a 'PRESS RELEASE | AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR'. It details 'record half-yearly sales in 2022' and outlines a 'new mid-term plan'. This content strongly indicates the release of periodic financial results (half-year results) and associated management commentary/outlook. This fits the definition of an Earnings Release (ER) which covers initial announcements of periodical financial results, or potentially an Interim/Quarterly Report (IR) if it were the comprehensive report. However, since it is presented as a press release announcing key figures, growth rates, and outlook, it aligns best with the 'Earnings Release' (ER) category, which typically precedes the full, detailed Interim Report (IR). Furthermore, the document mentions that the 'Half-Year Report 2022 as well as the HY 2022 results presentation are available' elsewhere, suggesting this document itself is the initial announcement/release, not the comprehensive report (IR) or the presentation (IP). The presence of a conference call schedule also supports the ER classification. H1 2022
2022-08-25 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.